摘要:
The present invention relates to compositions consisting essentially of a therapeutically effective amount of a compound selected from the group consisting of tetrahydro-isohumulone, tetrahydro-isocohumulone, and tetrahydro-isoadhumulone; and metformin, to be used in the treatment of an insulin related disorder, diabetes, obesity, or a cardiovascular disease.
摘要:
The present invention relates to the use of a composition comprising a synergistic combination of (a) at least one reduced isoalpha acid compound selected from the group consisting of dihydro-isohumulone, dihydro-isocohumulone, dihydro-isoadhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-isoadhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, and hexahydro-isoadhumulone, (b) at least one mineral, and (c) at least one vitamin for the manufacture of a medicament for the treatment of an autoimmune disease in a mammal; wherein the combination of (a), (b) and (c) provides a combination index (CI) of less than 1 for synergistic inhibition of PGE2 production.
摘要:
The present invention relates to a composition for treatment of inflammation comprising reduced isoalpha acid (RIAA) and methylxanthine in a synergistic ratio having a combination index (CI) of less than 1.
摘要:
The present invention relates to a composition for treatment of inflammation comprising reduced isoalpha acid (RIAA) and methylxanthine in a synergistic ratio having a combination index (CI) of less than 1.
摘要:
The present invention relates to compositions consisting essentially of a therapeutically effective amount of a compound selected from the group consisting of tetrahydro-isohumulone, tetrahydro-isocohumulone, and tetrahydro-isoadhumulone; and metformin, to be used in the treatment of an insulin related disorder, diabetes, obesity, or a cardiovascular disease.
摘要:
The present invention relates to compositions containing a reduces isoalpha acid and an isoalpha acid for use in reducing PGE2-mediated inflammation.